Evidence map›Paper›PMID 32974611›Full record

ArticleCerebral cortex communications2020

The Expression of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) in Hippocampal Arterioles Declines During Progression of Alzheimer's Disease.

Kelley E Anderson, Thomas A Bellio, Emily Aniskovich, Stephanie L Adams, Jan Krzysztof Blusztajn, Ivana Delalle

Open access · hybridAbstract read
In one paragraph

Article in Cerebral cortex communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kelley E AndersonDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Thomas A BellioDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Emily AniskovichDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Stephanie L AdamsDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Jan Krzysztof BlusztajnDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Ivana DelalleDepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Boston University · US

Funding

Age-Associated Lipidomic Changes in Alzheimer's DiseaseRF1AG057768 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF, STEIN, THOR · 2019 to 2021
$4.5M
BMP9 as a juvenile protective factor in cognitive agingR01AG045031 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF · 2014 to 2018
$1.8M
Juvenile trophic factors for the prevention and treatment of hippocampal agingR01AG032709 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF · 2008 to 2010
$1.1M
Age-Associated Lipidomic Changes in Alzheimer's DiseaseR56AG057768 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF, STEIN, THOR · 2017 to 2017
$820k
NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INIA NIH HHS R01 AG032709NIA NIH HHS R01 AG045031NIA NIH HHS R56 AG057768NIA NIH HHS RF1 AG057768
6 · The paper itself

Abstract

Cerebral amyloid angiopathy (CAA) in Alzheimer's disease (AD)-deposition of beta amyloid (Aβ) within the walls of cerebral blood vessels-typically accompanies Aβ buildup in brain parenchyma and causes abnormalities in vessel structure and function. We recently demonstrated that the immunoreactivity of activin receptor-like kinase 1 (ALK1), the type I receptor for circulating BMP9/BMP10 (bone morphogenetic protein) signaling proteins, is reduced in advanced, but not early stages of AD in CA3 pyramidal neurons. Here we characterize vascular expression of ALK1 in the context of progressive AD pathology accompanied by amyloid angiopathy in postmortem hippocampi using immunohistochemical methods. Hippocampal arteriolar wall ALK1 signal intensity was 35% lower in AD patients (Braak and Braak Stages IV and V [BBIV-V]; clinical dementia rating [CDR1-2]) as compared with subjects with early AD pathologic changes but either cognitively intact or with minimal cognitive impairment (BBIII; CDR0-0.5). The intensity of Aβ signal in arteriolar walls was similar in all analyzed cases. These data suggest that, as demonstrated previously for specific neuronal populations, ALK1 expression in blood vessels is also vulnerable to the AD pathophysiologic process, perhaps related to CAA. However, cortical arterioles may remain responsive to the ALK1 ligands, such as BMP9 and BMP10 in early and moderate AD.

Indexed as

ACVRL1ALK1hippocampusimmunohistochemistry

Identifiers

PMID32974611
PMCPMC7497413
OpenAlexW3046032372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.